Sorry, I don't understand your search. ×
Back to Search Start Over

STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications

Authors :
David A. Frank
Isidora Tošić
Source :
Neoplasia (New York, N.Y.), Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 12, Pp 1167-1178 (2021)
Publication Year :
2021
Publisher :
Neoplasia Press, 2021.

Abstract

The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is activated constitutively in a wide array of human cancers. It is an appealing molecular target for novel therapy as it directly regulates expression of genes involved in cell proliferation, survival, angiogenesis, chemoresistance and immune responsiveness. In addition to these well-established oncogenic roles, STAT3 has also been found to mediate a wide array of functions in modulating cellular behavior. The transcriptional function of STAT3 is canonically regulated through tyrosine phosphorylation. However, STAT3 phosphorylated at a single serine residue can allow incorporation of this protein into the inner mitochondrial membrane to support oxidative phosphorylation (OXPHOS) and maximize the utility of glucose sources. Conflictingly, its canonical transcriptional activity suppresses OXPHOS and favors aerobic glycolysis to promote oncogenic behavior. Apart from mediating the energy metabolism and controversial effects on ATP production, STAT3 signaling modulates lipid metabolism of cancer cells. By mediating fatty acid synthesis and beta oxidation, STAT3 promotes employment of available resources and supports survival in the conditions of metabolic stress. Thus, the functions of STAT3 extend beyond regulation of oncogenic genes expression to pleiotropic effects on a spectrum of essential cellular processes. In this review, we dissect the current knowledge on activity and mechanisms of STAT3 involvement in transcriptional regulation, mitochondrial function, energy production and lipid metabolism of malignant cells, and its implications to cancer pathogenesis and therapy.

Subjects

Subjects :
Cancer Research
p53, tumor protein 53
MEF2D, Myocyte Enhancer Factor 2D
FASN, fatty acid synthase
OXPHOS, oxidative phosphorylation
ERH, enhancer of rudimentary homolog
PDGF, platelet-derived growth factor
PFK, phosphofructokinase
CREB, cyclic AMP response element-binding protein
HDL-C, high-density lipoprotein cholesterol
chemistry.chemical_compound
PC, phosphatidylcholine
GRIM-19, gene associated with retinoid-IFN-induced mortality
Neoplasms
Transcriptional regulation
TGFβ, transforming growth factor beta
AML, acute myeloid leukemia
RC254-282
CDK, cyclin-dependent kinase
FABP6, fatty acid binding protein 6
BCL, B-cell lymphoma
CLL, chronic lymphocytic leukemia
Chemistry
LIF, leukemia inhibitory factor
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
VEGF, vascular endothelial growth factor
FBP1, fructose-bisphosphatase 1
GPI, glucose-6-phosphate isomerase
Cell biology
MMP, matrix metalloproteinase
STAT, signal transducer and activator of transcription
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
GP130, glycoprotein 130
Phosphorylation
NHL, non-Hodgkin's lymphoma
JAK, Janus kinase
Adenosine triphosphate
CNTF, ciliary neurotrophic factor
STAT3 Transcription Factor
ATP, adenosine triphosphate
TAG, triacylglycerol
Protein processing, Post-translational
PPARγ, peroxisome proliferator-activated receptor gamma
ETC, electron transport chain
TNFα, tumor necrosis factor alpha
RIME, rapid immunoprecipitation mass spectrometry of endogenous proteins
GLUT1, glucose transporter 1
PGK1, phosphoglycerate kinase
MPTP, mitochondrial permeability transition pore
Mediator
Review article
CML, chronic myeloid leukemia
HIF1α, hypoxia inducible factor 1α
PIAS, protein inhibitors of activated STATs
SOCS, suppressors of cytokine signaling
Animals
Humans
IFN, interferon
LDHA, lactate dehydrogenase A
Transcription factor
PKCδ, protein kinase C δ
TF, transcription factors
EGF, epidermal growth factor
SM, sphingomyelin
SREBP1, sterol regulatory element-binding protein 1
IAP, inhibitor of apoptosis
PTP, protein tyrosine phosphatases
Tyrosine phosphorylation
Lipid metabolism
BCSC, breast cancer stem cells
IL, interleukin
Metabolism
OSM, oncostatin M
Anaerobic glycolysis
NFκB, nuclear factor kappa B
TBK1, TANK-binding kinase 1
MCL, myeloid cell leukemia
LDL-C, low-density lipoprotein cholesterol
PBP, PPARγ binding protein
CPT1B, carnitine palmitoyltransferase 1B
FAO, fatty acid oxidation

Details

Language :
English
ISSN :
14765586 and 15228002
Volume :
23
Issue :
12
Database :
OpenAIRE
Journal :
Neoplasia (New York, N.Y.)
Accession number :
edsair.doi.dedup.....95fc1e221705a2edcb47149735290583